Catheter renal denervation in treatment of resistant hypertension: reality or fiction?

Czech version

Authors: Miloš Táborský
Authors‘ workplace: I. interní klinika – kardiologická LF UP a FN Olomouc, přednosta prof. MUDr. Miloš Táborský, Ph. D., FESC, MBA
Published in: Vnitř Lék 2014; 60(4): 380-388
Category: 60th Birthday - prof. MUDr. Petr Widimský, DrSc., FESC, FACC

Overview

Catheter renal denervation is one of the most dynamically emerging subspecialties in cardiology in the last five years. Initial indications for the treatment of resistant hypertension have been extended to other research areas – sleep apnea syndrome, heart failure, insulin resistance, atrial fibrillation, ventricular tachycardias and many others. Just as in other areas of cardiology, for example, the issue of stem cells, was unfortunately little space devoted to experimental studies and clinical studies phase II. Clinical application was ahead of a substantial part of the development of new technologies. Originally Symplicity HTN-1 and -2 showed promising results, now have been recently challenged by early termination of the Symplicity HTN-3 study, which had significantly harder endopoints than previous studies. What was the precise cause of the inefficiency of this treatment, it is currently impossible to say exactly. Interesting conclusions could bring original Czech study PRAGUE 15, designed by professor Petr Widimský, where control treatment in both arms is verified by gold standard – ambulatory blood pressure monitoring and as well emphasis the compliance of the pharmacology treatment.

Key words:
renal denervation – resistant hypertension – radiofrequency energy

Sources

1. World Health Statistics 2012. World Health Organization (WHO) 2012. ISBN 978 92 4 156444 1. Dostupné z WWW: <http://apps.who.int/iris/bitstream/10665/44844/1/9789241564441>.

2. Murray CJ, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990- 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2197–2223.

3. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217–223.

4. Egan BM, Zhao Y, Axon RN US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010; 303(20): 2043–2050.

5. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117(25): e510-e526. Dostupné z DOI: <http:// doi: 10.1161/CIRCULATIONAHA.108.189141>.

6. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125(13): 1594–1596.

7. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–1357.

8. Chytil L, Štrauch B, Cvačka J et al. Determination of doxazosin and verapamil in human serum by fast LC–MS/MS: Application to document non-compliance of patients. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878(30): 3167–3173.

9. Sobotka PA, Mahfoud F, Schlaich MP et al. Sympatho-renal axis in chronic disease. Clin Res Cardiol 2011; 100(12): 1049–1057.

10. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77(1): 75–197.

11. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev 1991; 71(3): 659–682.

12. Dorr O, Liebetrau C, Möllmann H et al. Renal sympathetic denervation does not aggravate function or structural renal damage. J Am Coll Cardiol 2013; 61(4): 479–484.

13. Prochnau D, Figulla HR, Surber R. Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring – long-term follow-up. Int J cardiol 2012; 157(3): 447–448.

14. Davis MI, Filion KB, Zhang D et al. Efectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol 2013; 62(3): 231–241.

15. Mahfoud F. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34(28):2149–2157. Dostupné z DOI: <http://doi:10.1093/eurheartj/eht154>.

16. Widimský P, Filipovský J, Widimský jr. J et al. Expert consensus statement of the Czech Society of Cardiology and Czech Society of Hypertension on catheter-based sympathetic renal denervation procedures (RDN) in the Czech republic. Cor Vasa 2012; 54(2): e108-e112.

17. Schlaich MP, Schmieder RE, Bakris G et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013; 22(62): 2031–2045.

18. Schlaich MP, Sobotka PA, Krum H et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54(6): 1195–1201.

19. Esler MD, Krum H, Schlaich M et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012; 126(25): 2976–2982.

20. Böhm M. Three-Year Results from Symplicity HTN-1 and Symplicity HTN-2: What the Data Do (and Don’t) Tell Us. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference, Miami, FL, US, October 22–26, 2012.

21. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57(5): 911–917.

22. Symplicity HTN-2 Investigators, Esler MD, Krum H et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903–1909.

23. Esler M. BP reductions with renal denervation durable to 30 months: Symplicity HTN-2, Presented at: ASH conference, San Francisco, US, 15–18 May 2013.

24. Kandzari DE, Bhatt DL, Sobotka PA et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35(9): 528–535.

25. Podrobnější informace dostupné z DOI: <http://www.tctmd.com/show.aspx?id=123265>.

26. Potthoff SA, Rump LC, Vonend O The “resistant hypertension team”: focus on a multidisciplinary approach to hypertension. EuroIntervention 2013; 9: (Suppl R): R48-R53.

27. Podrobnější informace dostupné z DOI: <http://www.medscape.com/viewarticle/817482>.

28. Mountfort K. Catheter-based Renal Sympathetic Denervation – Long-term Symplicity™ Renal Denervation Clinical Evidence, New Data and Future Perspectives. Interventional Cardiology Review 2013; 8(2): 118–123.

29. Toušek P, Widimský jr. J, Rosa J et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of the multicenter randomized study – PRAGUE 15. Odesláno k publikaci.

30. Bhatt DL, Kandzrai DE, O´Neill WW et al. A controlled trial of renal denervation for resistant hypertension. New Engl J Med 2014; 370(15):1393–1401.